Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (39)	1/30/2002 11:18:42 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 95

Linda Nardone, Ph.D., RAC Vice President of Clinical and Regulatory Affairs Dr. Nardone has 16 years of experience in both big pharmaceutical and start-up biotechnology companies, accompanied by a solid academic career in biochemistry and cell biology. Prior to EluSys, Dr. Nardone served as Vice President of Regulatory Affairs at Coulter Pharmaceuticals, Inc., guiding regulatory strategies for Coulter's lead product, BexxarTM, a monoclonal antibody for the treatment of non-Hodgkin's lymphoma. In the process, she became one of a select number of pharmaceutical veterans with extensive regulatory experience in monoclonal antibodies. elusys.com